# A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

> **NCT04594369** · PHASE3 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 1767 (actual)

## Conditions studied

- Non-Cystic Fibrosis Bronchiectasis

## Interventions

- **DRUG:** Brensocatib 10 mg
- **DRUG:** Brensocatib 25 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04594369
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2024-10-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 1767 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594369, "A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04594369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*